Biomarker Consortium launches
This article was originally published in The Gray Sheet
Executive Summary
The American College of Radiology Imaging Network's (ACRIN) planned clinical trial exploring the use of fluorodeoxyglucose positron emission tomography (FDG-PET) to evaluate non-Hodgkins lymphoma and lung cancer patients' response to therapy is the first project supported by the Biomarker Consortium, a newly formed research partnership between the Foundation for the National Institutes of Health, NIH, FDA, CMS and industry and patient groups, according to an Oct. 5 release. The consortium will identify and validate new biological markers to advance the science of personalized medicine. "Imaging tests such as PET scanning can potentially reduce both suffering and cost for cancer patients by providing better selection of appropriate treatment and determining earlier ... whether treatment will be effective," ACRIN explains. Depression and diabetes are further areas of prospective study cited by the consortium...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.